Rite Aid and Elixir: Rebates Reported as Service Fees

In the Rite Aid Elixir rebate settlement, Rite Aid and Elixir Insurance agreed to pay $101 million over allegations that they reported manufacturer rebates as service fees in Medicare Part D. The government alleged that the manufacturers had never negotiated to pay those fees. For someone working in rebate accounting or manufacturer contracting, that is the heart of the case: money received under a rebate arrangement acquired a different identity in the report to Medicare.

The Justice Department announced the agreement on July 10, 2024. This pharmaceutical fraud case began with a former RX Options employee’s qui tam action. The alleged reporting covered 2014 through 2020 and involved Rite Aid Corporation and its subsidiaries Elixir Insurance Company, RX Options LLC and RX Solutions LLC. Besides running one of the country’s largest retail pharmacy chains, Rite Aid offered Medicare drug plans and pharmacy benefit manager services through those three subsidiaries.

What Was Reported to Medicare Part D?

The government alleged that the defendants reported portions of manufacturer rebates as bona fide service fees in Part D direct and indirect remuneration reports, the yearly reports of rebates and other manufacturer payments to the Centers for Medicare and Medicaid Services. That classification affected the money Medicare accounted for when settling up with the plan.

Medicare Part D delivers outpatient prescription drug coverage through private plans. Those plans and their pharmacy benefit managers negotiate manufacturer rebates. Part D sponsors report rebates and other manufacturer payments each year so the government receives the benefit of price concessions.

The year-end calculation matters. Medicare reconciles payments using allowable drug costs after rebates and other discounts. A rebate reduces the cost that goes into that calculation. Treating the same receipt as an excluded service fee keeps that reduction out of the report and leaves taxpayers paying against a higher drug cost.

That is why PBM rebate reporting reaches beyond the total on a manufacturer payment statement. The money received, its classification and the amount reported to Medicare have to tell the same story. The government alleged that Elixir Insurance knew the retained rebates did not meet the definition of bona fide service fees.

Sponsors disclose negotiated manufacturer concessions in the aggregate, and that information is confidential. An employee who understands how a rebate receipt becomes a reporting entry can see a decision that the final total conceals.

Why Call a Rebate a Service Fee?

A bona fide service fee receives different treatment from a price concession. The alleged advantage in this case was excluding retained rebates from the Part D calculation by calling them payment for services.

The bona fide service-fee test asks about the transaction behind the name. Its conditions concern fair market value, an itemized service actually performed for the manufacturer, work the manufacturer would otherwise perform or purchase, and a payment that is not passed on to the recipient’s client or customer.

Each condition asks something different. A service description identifies the work. Performance records show whether somebody did it. The manufacturer’s arrangement explains why it bought the work, while the valuation addresses what that work was worth. The payment trail shows whether the fee stayed with the service provider or moved on to a client.

A ledger category answers none of those questions by itself. The Justice Department’s allegation was particularly direct: manufacturers had not negotiated to pay the fees the defendants reported. The government also alleged knowledge at Elixir Insurance.

For a contracting employee, the service agreement and the rebate agreement may explain why the money arrived. For an accountant, the classification explains where it went in the calculation. Our work connects those views of the same payment to what the government was told.

Do Pharmacy Benefit Managers Have a Role in the Prescription Drug Supply Chain?

Pharmacy benefit managers negotiate with manufacturers and operate between drug plans and the pharmacies their members use. Their formulary work also helps determine which drugs a health plan covers, giving manufacturers a commercial reason to negotiate rebates.

The Oregon Law Review’s 2020 paper on pharmacy benefit manager rebates explains how formulary access gives pharmacy benefit managers bargaining power and how opaque rebate arrangements can conceal retained revenue. Its proposed approach to administrative fees put the work itself at the center:

That proposal makes the manufacturer’s service arrangement central to understanding a fee, just as the absence of negotiated fees was central to the Elixir allegations.

Pharmacy benefit managers also earn revenue through the difference between what a plan pays them for a prescription and what they reimburse the pharmacy. That spread follows the pharmacy-payment trail. A manufacturer rebate follows the manufacturer’s agreement and payment. Keeping those transactions distinct lets an insider explain exactly which revenue changed categories.

The Payment Agreement and the Bankruptcy Claim

Rite Aid and Elixir Insurance agreed to pay the United States. RX Options and RX Solutions granted a separate $20 million claim in the bankruptcy. The claim was a right to seek payment from the bankruptcy estate, not another cash payment in the announced amount. The settlement was based on the companies’ ability to pay, and the bankruptcy court approved it on June 28 as part of Rite Aid’s plan of reorganization. The whistleblower’s share had not been determined when the settlement was announced.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

What an Insider’s Records Can Show

The useful connection runs from the manufacturer’s agreement to the money received, the fee classification and the annual Medicare report. In a case about rebates reported as service fees, our whistleblower experts examine what the manufacturer agreed to purchase, how the payment was valued and which report ultimately carried it.

An agreement can identify a service and its price. An invoice and records of completed work can show what the manufacturer received. The rebate ledger and reporting calculations can show whether the same money was treated as a concession or a fee. Internal decisions about that treatment matter alongside the arithmetic, particularly where the government alleges the company knew its classification was wrong.

A public procurement document makes the contract side concrete. Sandia National Laboratories’ pharmacy benefits manager statement of work, for services beginning in 2013, defined rebates to include associated administrative and data fees attributable to its members’ prescriptions. It required those rebates to pass through to Sandia and be fully auditable. The name attached to a manufacturer payment did not, by itself, put that payment outside the contractual rebate definition.

The statement also required quarterly rebate reports with associated claim counts. Its audit provisions reached paid claims, the formulary rebate program, reporting to manufacturers, accounting for rebates earned and allocation of rebate payments to Sandia. Those terms show what a health care purchaser wanted to see behind the rebate total.

In the Elixir matter, the additional connection was to the Part D report and Medicare’s reconciliation. For a healthcare insider, knowing where that chain changed can be more revealing than knowing the final rebate total.

The Same Fee Label, a Different Government Calculation

Other pharmaceutical cases show why the service-fee label has to be followed into the particular government calculation. In the AstraZeneca and Cephalon settlements, the government alleged that manufacturers improperly deducted wholesaler service fees from average manufacturer prices. Lower reported prices reduced the quarterly rebates owed to state Medicaid programs.

The Bristol-Myers Squibb settlement addressed similar service-fee deductions and another alleged omission: value returned to the manufacturer under price-appreciation provisions in wholesaler contracts. Those provisions concerned the gain on inventory a wholesaler already held when a manufacturer raised its price.

The direction of the alleged manipulation matters. In those Medicaid cases, deducting service fees pushed the reported manufacturer price down and reduced the manufacturer’s rebate bill. In the Elixir case, the government alleged that calling rebates service fees kept price concessions out of the Part D calculation. The reporting point had moved from the manufacturer to the plan and PBM layer, but the central comparison remained the payment’s commercial purpose against its treatment in a government report. A person who knows what the payment bought may hold the fact that explains why the reported drug price or cost is wrong.

You Know Why the Payment Arrived

If you worked on manufacturer contracts, rebate accounts or Part D reports and saw rebates turned into service fees, tell our whistleblower experts where the treatment changed. We build the case around the transaction you understand, bring in Medicare Part D whistleblower lawyers who know rebate reporting, and stay with you through the pursuit of a recovery.